ArticleCancer discovery2020

Targeting HER2 with Trastuzumab Deruxtecan: A Dose-Expansion, Phase I Study in Multiple Advanced Solid Tumors.

Junji Tsurutani et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.